Preliminary Study of Peel Force and Discomfort of Removal of Adhesive Barriers in Normal and Peristomal Skin

October 5, 2016 updated by: Hollister Incorporated
This purpose of this study is to look at three commercially available ostomy barriers on peristomal (around the stoma) skin. Repeated barrier application and removal over years causes changes to the skin that the investigators wish to investigate. The primary objective is to measure peel force on normal skin and peel force on peristomal skin, with the intent of determining if differences occur. The study hypotheses is that no differences exist.

Study Overview

Detailed Description

This is a single center, non-invasive exploratory study utilizing a sample of convenience. This study compares three commercially available barrier materials on peristomal skin and normal abdominal skin.

Study Type

Observational

Enrollment (Actual)

17

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Illinois
      • La Grange Park, Illinois, United States, 60526
        • La Grange Center for Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Ostomates with a normal peristomal skin and normal ipsilateral abdominal skin

Description

Inclusion Criteria:

  • Colostomy, Ileostomy, or Urostomy patients at least 6 months post-surgery
  • Males or females, age 18 to 80 years old at the time of enrollment
  • Body Mass Index (BMI) between 18 and 50
  • Willing to have two approximately 5" x 5" areas of the abdomen trimmed with a surgical clipper -- one in a ring around the stoma, and one on the opposite side
  • Willing to remain within the testing room for the duration of the study
  • Willing to allow a third person in the room as a witness for the duration of the study
  • Able to position oneself onto and off of the examining table without the assistance of the Investigator
  • Willing to refrain from vigorous exercise for the duration of the study
  • Willing to not take any anti-inflammatory medications (except for Tylenol/acetaminophen) starting 48 hours prior to the study and for the duration of the study
  • Willing to bring an extra barrier and replace their barrier worn during the study.
  • Willing to follow the protocol as demonstrated by signing the Informed Consent Form
  • In the opinion of the Investigator or qualified site personnel is qualified to participate

Exclusion Criteria:

  • Clinically significant diseases, which may or may not be confined to the testing site, that may contraindicate participation; including but not limited to psoriasis, eczema, atopic dermatitis, and active cancer
  • Use of topical drugs on the application site within 1 month.
  • Use of lotions, creams, powders or oils on the application site in the 24 hours prior to application
  • Pregnancy, lactation or planning a pregnancy as determined by interview only
  • Other medical conditions, for example uncontrolled diabetes, which in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk
  • Participation in any clinical test either using the abdomen as a test site or using systemic therapy within the previous thirty days
  • Damaged skin or other skin conditions in or near test sites which includes sunburn, scars, numerous moles or other disfiguration of the test site
  • Significant adipose tissue at the test site that would preclude adequate adhesion of the study devices
  • Known allergy to any of the test materials

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Control Abdominal Skin
Apply SoftFlex (standard wear commercial skin barrier), FlexWear (standard wear commercial skin barrier), and FlexTend (extended wear commercial skin barrier), material to non-peristomal abdominal skin.
Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
Other Names:
  • SoftFlex
  • FlexWear
  • FlexTend
Peristomal Abdominal Skin
Apply SoftFlex, FlexWear and FlexTend barrier material to peristomal abdominal skin.
Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
Other Names:
  • SoftFlex
  • FlexWear
  • FlexTend

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Skin Barrier Peel Force
Time Frame: 4 hours
Peel force of barrier materials, comparing peristomal skin to abdominal skin. A portable peel force analyser, previously validated, was used in the clinic to measure peel at 90 degrees to the plane of the body. Peel force was measured on peristomal skin and ipsilateral abdominal skin in the same subject.
4 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: James Swan, MD, Loyola University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2013

Primary Completion (Actual)

February 1, 2014

Study Completion (Actual)

February 1, 2014

Study Registration Dates

First Submitted

November 20, 2013

First Submitted That Met QC Criteria

December 5, 2013

First Posted (Estimate)

December 6, 2013

Study Record Updates

Last Update Posted (Estimate)

November 11, 2016

Last Update Submitted That Met QC Criteria

October 5, 2016

Last Verified

October 1, 2016

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 5642-O
  • LUHSC IRB #: 205654091813 (Other Identifier: Hollister Incorporated)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dermatologic Complications

Clinical Trials on Control Abdominal Skin

3
Subscribe